Phase 1 study of AB-1002 (cardiotropic AAV delivering I-1c) in 11 patients with nonischemic HFrEF showed feasibility, no treatment-attributed SAEs, transient LFT elevations at higher dose, and preliminary signals of improved LVEF and NYHA class, supporting further randomized trials.